研發與技術
R&D and Technology
2023-A Randomized Double-Blind Parallel-Controlled Phase I Study Comparing the Pharmacokinetics Safety and Immunogenicity of SCT510 to Bevacizumab (Avastin®) in Healthy Chinese Males
2023-06-01
999+
學術論著
上一篇：2023-Antitumor activity of pegylated human interferon β as monotherapy or in combination with immune checkpoint inhibitors via tumor growth inhibition and dendritic cell activation-汪瑞
下一篇：2023-A Polysaccharide-RBD-Fc-Conjugated COVID-19 Vaccine SCTV01A Showed High Immunogenicity and Low Toxicity in Animal Models
最新資訊
-
2024-SCT-I10A combined with a bevacizumab biosimilar (SCT510) versus sorafenib in the first-line treatment of advanced hepatocellular carcinoma A randomized phase 3 trial
2024-06-20 -
2024-Rapid development and mass production of SARS-CoV-2 neutralizing chicken egg yolk antibodies with protective efficacy in hamsters
2024-05-06 -
2024-Immunogenicity of Tetravalent Protein Vaccine against SARS-CoV-2 EG.5 Subvaraint A Phase 2 Trial
2024-02-08 -
2024-Finotonlimab with chemotherapy in recurrent or static head and neck cancer a randomized phase 3 trial
2024-06-02